PEPTIDE COMPARISON

MOTS-c vs SS-31

Two mitochondrial peptides with sharply different clinical status.

QUICK ANSWER

MOTS-c vs SS-31: the main difference.

SS-31, as elamipretide, has crossed a regulatory threshold for one rare-disease use; MOTS-c has not. Neither evidence base supports broad longevity or performance claims.

Decision field	MOTS-c	SS-31 / Elamipretide
Human research	Small physiology studies	Small rare-disease clinical program
Primary research	Exercise and metabolic signaling	Mitochondrial cardiolipin and Barth syndrome
FDA status	Not approved	Accelerated approval for one Barth syndrome indication
Core evidence problem	Endogenous biology is treated as therapy evidence	Narrow approval is generalized to longevity
Evidence confidence	Very low for therapeutic use	Moderate for the labeled rare-disease use

SOURCES

MOTS-c vs SS-31 sources.

Preclinical / 2021MOTS-c and age-dependent physical declineNature Communications / PubMed Human trial / 2021Circulating mitochondrial-derived peptides after exercisePubMed FDA / 2026Bulk substances that may present significant safety risksU.S. FDA FDA / 2025FDA grants accelerated approval to first treatment for Barth syndromeU.S. FDA FDA / 2025Forzinity prescribing informationU.S. FDA

MOTS-c vs SS-31: the main difference.

MOTS-c vs SS-31 sources.

Questions related to MOTS-c vs SS-31.

Compare the next decision.